Sentences with word «ibrutinib»

The new data builds off several preclinical studies supporting the use of ibrutinib with CAR therapy.

The US Food and Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.

«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online by JAMA Oncology.

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high - risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center (ACC).

Combining ibrutinib with the CTL119 therapy achieved very powerful results for patients in the pilot study, and with limited toxicity.

All patients received ibrutinib.

Based on this study's results, an international phase III trial of standard chemotherapy with or without ibrutinib in patients with DLBCL, excluding the GCB subtype, is being conducted by Janssen Pharmaceuticals, Titusville, New Jersey, in collaboration with Drs. Wilson and Staudt.

Patients in the trial had been on ibrutinib for a minimum of six months and had not achieved a complete response when they received an infusion of engineered cells split over three consecutive days.

The team will present on the first 10 patients in the trial, each of whom had been taking ibrutinib for at least six months but had not achieved a complete remission.

Jennifer A. Woyach, M.D., of Ohio State University, Columbus, and coauthors described the characteristics of patients who discontinued ibrutinib therapy and their outcomes in a group of 308 patients participating in four trials at a single institution.

The results suggest that ibrutinib restored T cell activity in the patients.

Based on these results, the researchers concluded that, for future clinical trials involving ibrutinib, the ABC DLBCL gene signature could be used to identify patients who would be more likely to respond to the drug.

An analysis based on disease subtype showed that ibrutinib produced complete or partial responses in 37 percent (14 of 38) of patients with ABC DLBCL but only 5 percent (1 of 20) of patients with GCB DLBCL.

For example, a drug called ibrutinib has been tested in clinical trials to treat an aggressive form of non-Hodgkin lymphoma, diffuse large B - cell lymphoma (DLBCL).

Finally, the researchers were able to predict from the ctDNA sequences those patients whose disease was transforming into a much more aggressive form prior to the emergence of clinical symptoms, and even to identify and track specific mutations known to inhibit the response to the targeted therapy with a drug known as ibrutinib.

The targeted agent ibrutinib has shown a high response rate in both treatment - naive and previously treated, relapsed, refractory chronic lymphocytic leukemia (CLL) patients older than 65.

Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.

This approval was granted based on the results of a phase II study of 63 qualifying patients receiving 560 - mg ibrutinib once daily.

«Combining ibrutinib with the CTL119 therapy achieved very powerful results for these patients, and with limited toxicity,» Gill said.

All patients received ibrutinib 560 mg once daily.

A clinical trial has shown that patients with a specific molecular subtype of diffuse large B - cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.

The study's objective is to determine if the addition of ibrutinib to standard chemotherapy can increase the cure rate of patients with ABC DLBCL.

Last year, the U.S. Food and Drug Administration recognized the promise of both drugs, designating them «breakthrough therapies» — ibrutinib for chronic GVHD and ruxolitinib for the acute disease.

In March 2016, Penn researchers published a study in Blood that showed long - term ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in mice.

«This single - institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation.

Longer follow - up will reveal the durability of these results, the authors said, and may support the evaluation of a first - line approach with ibrutinib and CAR therapy in an effort to remove the need for chronic therapy.

In this phase II trial, patients with the activated B - cell - like (ABC) subtype of DLBCL were more likely to respond to ibrutinib than patients with the germinal center B - cell - like (GCB) subtype of DLBCL.

The target for ibrutinib, an enzyme called Bruton's tyrosine kinase (BTK), is a key component of B - cell receptor signaling.

The new study provides the first clinical evidence that ABC but not GBC tumors may produce abnormal B - cell receptor signals that promote the survival of cancer cells by activating BTK, thereby accounting for the sensitivity of ABC tumors to ibrutinib.

Unfortunately, the response to ibrutinib has been limited only to a subgroup of DLBCL patients.

The lab of Elisa Oricchio at EPFL has now carried out a study to identify mechanisms of resistance to ibrutinib.

In July 2015, his muscles wasting away, Wartman joined a clinical trial of a drug, ibrutinib, approved to treat specific blood cancers.